

## Bölüm 14

# Optik Nöropatiler


Erdoğan Yaşar<sup>1</sup>

### GİRİŞ

Optik sinir, retina ganglion hücrelerinin aksonlarından oluşmakta olup tek gözde yaklaşık 1-1.2 milyon akson bulunmaktadır. Her iki gözden çıkan optik sinirler, optik kiazma bölgesinde birleşirler. Optik sinir aynı zamanda ikinci kranial sinir olarak da bilinmektedir. Görme uyarısının sinirsel iletili yanında ışık refleksinin afferent liflerini de taşımaktadır. Aynı zamanda beynin bir uzantısı olduğu için beyni ve medulla spinalis saran meninks zarları içten dışa doğru pia mater, araknoid mater ve dura mater olmak üzere optik siniri de sarmaktadır. Dura mater orbita içinde 2 bölüme ayrılmakta olup yapraklardan biri orbitayı döşemekte diğeri ise sklera ile kaynaşmaktadır. Araknoid zarı altındaki boşlukta beyin omirilik sıvısı bulunmakta olup kafa içi basıncının arttığı durumlarda papil ödem görünümüne neden olmaktadır. Schwann kılıfı ile sarılı olmadığı için rejenerasyon yeteneği olmayan optik sinir ciddi hasarlarında geri dönüşümsüz görme kaybı gelişebilmektedir. Retina gangliyon hücrelerinden oluşan optik sinir kiazma, optik traktuslar, korpus geniculatum laterale ve daha sonra optik radyasyon aracılığı ile Brodman 17 no'lu alan olarak adlandırılan medial oksipital loptaki kalkarin kortekse ulaşmaktadır. Görme korteksinin beslenmesi medial ve posterior serebral damarlar aracılığı ile olmaktadır.

Optik sinirin beslenmesinde, internal karotis arterin ilk major dalı olan oftalmik arter; optik kanal içinde , optik sinirin inferiorunda ve sinirden dura kılıfı ile ayrılmış olarak seyrederek optik sinirin büyük bölümünün beslenmesini gerçekleştirir. Orbita içinde, oftalmik arter, pial damarları ve 2 yada 3 posterior siliyer arter dallarını verdikten sonra santral retinal arter olarak devam etmektedir. Santral retinal arter, glokun yaklaşık 8-12 mm posteriorunda optik sinir içine girerek sinir içinde seyreder.

<sup>1</sup> Dr. Öğr. Üyesi, Aksaray Üniversitesi Aksaray Eğitim ve Araştırma Hastanesi Göz Hastalıkları ABD., dr.e.yasar@gmail.com



Resim 7a, 7b: Sağ gözde daha fazla olmak üzere bilateral papil ödemi olan Psödötümör Serebri olgusunun fundus fotoğrafları

Papilödem tespit edilir edilmez mutlaka psödo papilödem ödem ayırıcı tanısı yapıldıktan sonra acil nörolojik konsültasyon istenmelidir. Başağrısı, bulantı, kusma, çınlama ve bilateral 6. kraniyal sinire bası sonucu horizontal diplopi eşlik edebilen ek sistemik bulgulardır. Papilödem her iki gözde de olup görme keskinliği ve ışık refleksi optik atrofi oluşuncaya kadar normal olarak saptanır. Optik nörit olan papillitten farklı olarak göz hareketleri ile ağrı yoktur. Tedavisi etiyojisine yönelik olup eğer optik atrofi gelişmeden önce başlanırsa genellikle prognoz iyidir. Ayrıca optik sinir fenestrasyonu ve şant cerrahisi seçilmiş vakalarda fayda sağlayabilmektedir.

**Anahtar Kelimeler:** İskemik optik nöropati, toksik-nütrisyonel optik nöropati, travmatik optik nöropati, kompresif-infiltratif optik nöropati, papil ödem

## KAYNAKÇA

1. Hayreh SS. Anatomy and physiology of the optic nerve head. *Trans Am Acad Ophthalmol Otolaryngol.* 1974; 78: 240-54.
2. Hernandez MR, Igoe F, Neufeld AH. Extracellular matrix of the human optic nerve head. *Am J Ophthalmol.* 1986;102:139-148.
3. Yıldırım E. (2003). Anatomi ve Histoloji. Turaçlı E, Önel M, Yalvaç IS. *Glokom.* (s:19-24) Ankara: SFN yayınevi, 19-24.
4. Miller NR, Newman NJ, Bioussé V, Kerrison JB. Walsh & Hoyt's. (2005). *Clinical Neuro-Ophthalmology.* 6 th Ed, Philadelphia, Pennsylvania, Baltimore, Maryland: Lippincott Williams & Wilkins.
5. Varma, R., Tielsch, J. M., Quigley, H. A., Hilton, S. C., Katz, J., Spaeth, G. L., & Sommer, A. Race-, age-, gender-, and refractive error-related differences in the normal optic disc. *Archives of ophthalmology.* 1994;112(8):1068-1076.
6. Jonas JB, Budde WM, Panda-Jonas S. Ophthalmoscopic evaluation of the optic nerve head. *Surv Ophthalmol.* 1999;43:293-320.
7. Britton RJ, Drance SM, Schulzer MD, et al. The area of the neuroretinal rim of the optic nerve in normal eyes. *Am J Ophthalmol.* 1987; 103: 497-504.
8. Kelman SE. (1997). Ischemic optic neuropathies. In: Miller NR, Newman NJ, eds. *Walsh & Hoyt's Clinical Neuro-Ophthalmology Vol.1.* 2nd ed. (549-98). Baltimore: Williams & Wilkins

9. Hayreh SS, Joos KM, Podhajsky PA, et al. Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. *Am J Ophthalmol.* 1994;118:766-80.
10. Hattenhauer MG, Leavitt JA, Hodge DO, et al. Incidence of nonarteritic anterior ischemic optic neuropathy. *Am J Ophthalmol.* 1997;123:103-7.
11. Newman, N. J., Dickersin, K., Kaufman, D., Kelman, S., & Scherer, R. Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the Ischemic Optic Neuropathy Decompression Trial. *Archives of Ophthalmology.* 1996;114(11):1366-1374.
12. Johnson LN, Arnold AC. Incidence of nonarteritic and arteritic anterior ischemic optic neuropathy. Population-based study in the state of Missouri and Los Angeles County, California. *J Neuroophthalmol* 1994;14:38-44.
13. Valerie Purvin. Ischemic optic neuropathy. *Seminars in Cerebrovascular Diseases and Stroke* 2004;4:18-38.
14. Hayreh SS. Factors influencing blood flow in the optic nerve head. *J. Glaucoma* .1997;6:412-25.
15. Hayreh SS, Zimmerman MB, Podhajsky P, et al. Nocturnal arterial hypotension and its role in optic nerve head and ocular ischemic disorders. *Am J Ophthalmol.* 1994;15(117):603-24.
16. Acheson JF, Sanders MD. Coagulation abnormalities in ischemic optic neuropathy. *Eye.* 1994;8:88-92.
17. Talks SJ, Chong NH, Gibson JM et al. Fibrinogen, cholesterol and smoking as risk factors for non-arteritic anterior ischaemic optic neuropathy. *Eye* 1995;9:85-8.
18. Burde RM. Optic disk risk factors for nonarteritic anterior ischemic optic neuropathy. *Am J Ophthalmol.* 1993;15;116:759-64.
19. Mojon DS, Hedges TR, Ehrenberg B, et al. Association between sleep apnea syndrome and nonarteritic anterior ischemic optic neuropathy. *Arch Ophthalmol.* 2002;120:601-5.
20. Costea CF, Petraru D, Galan B, et al. The correlation between anterior ischemic optic neuropathy the non-arthritis form, and the treatment involving alpha-interferon. *Rev Med Chir Soc Med Nat Iasi* 2013;117:942-6.
21. Doro S, Lessell S. Cup-disc ratio and ischemic optic neuropathy. *Arch Ophthalmol.* 1985;103:1143-4.
22. Galvez-Ruiz A, Arishi N. Sequential, non-arteritic anterior ischemic optic neuropathy in patients taking sildenafil: a report of ten cases. *Saudi J Ophthalmol.* 2013;27:241-6.
23. Chiari M, Manzoni GC, Van de Geijn EJ. Ischemic optic neuropathy after sumatriptan in a migraine with aura patient. *Headache.* 1994;34:237-8.
24. Burde RM. Optic disk risk factors for nonarteritic anterior ischemic optic neuropathy. *Am J Ophthalmol.* 1993;116:759-64.
25. Guyer DR, Miller NR, Auer CL, et al. The risk of cerebrovascular and cardiovascular disease in patients with anterior ischemic optic neuropathy. *Arch Ophthalmol.* 1985;103:1136-42.
26. Hayreh SS, Joos KM, Podhajsky PA, et al. Systemic diseases associated with nonarteritic anterior ischemic optic neuropathy. *Am J Ophthalmol.* 1994;118: 766-80.
27. Weger M, Stanger O, Deutschmann H, et al. Hyperhomocyst(e)inaemia, but not MTHFR C677T mutation, as a risk factor for non-arteritic ischaemic optic neuropathy. *Br J Ophthalmol.* 2001;85:803-6.
28. Worrall BB, Moazami G, Odel JG, et al. Anterior ischemic optic neuropathy and activated protein C resistance. A case report and review of the literature. *J Neuroophthalmol.* 1997;17:162-5.
29. Fingert JH, Grassi MA, Janutka JC, et al. Mitochondrial variant G4132A is associated with familial non-arteritic anterior ischemic optic neuropathy in one large pedigree. *Ophthalmic Genet.* 2007;28:1-7.
30. Salomon O, Rosenberg N, Steinberg DM, et al. Nonarteritic anterior ischemic optic neuropathy is associated with a specific platelet polymorphism located on the glycoprotein Ibalpha gene. *Ophthalmology.* 2004;111:184-8.
31. Johnson LN, Kuo HC, Arnold AC. HLA-A29 as a potential risk factor for nonarteritic anterior ischemic optic neuropathy. *Am J Ophthalmol.* 1993;115: 540-2.
32. Salomon O, Huna-Baron R, Steinberg DM, et al. Role of aspirin in reducing the frequency of

- second eye involvement in patients with non-arteritic anterior ischaemic optic neuropathy. *Eye*.1999;13:357-9.
33. Beck RW, Hayreh SS, Podhajsky PA, et al. Aspirin therapy in nonarteritic anterior ischemic optic neuropathy. *Am J Ophthalmol*. 1997;123:212-7.
  34. Botelho PJ, Johnson LN, Arnold AC. The effect of aspirin on the visual outcome of nonarteritic anterior ischemic optic neuropathy. *Am J Ophthalmol*. 1996;121:450-1.27. 28.
  35. Hayreh SS, Zimmerman MB. Optic disc edema in non-arteritic anterior ischemic optic neuropathy. *Graefes Arch Clin Exp Ophthalmol*. 2007;245:1107-21.
  36. Menzi J, Körner F. Systemic corticosteroid therapy in non-arteritic anterior ischemic optic neuropathy *Klin Monbl Augenheilkd*.1992;200:349-53.50.
  37. Rebolleda G, Pérez-López M, Casas-Llera P, et al. Visual and anatomical outcomes of non-arteritic anterior ischemic optic neuropathy with high-dose systemic corticosteroids. *Graefes Arch Clin Exp Ophthalmol*. 2013;251:255-60.
  38. Yaman A, Selver OB, Saatci AO, et al. Intravitreal triamcinolone acetate injection for acute non-arteritic anterior ischaemic optic neuropathy. *Clin Exp Optom*. 2008;91:561-4.
  39. Kaderli B, Avci R, Yucel A, et al. Intravitreal triamcinolone improves recovery of visual acuity in nonarteritic anterior ischemic optic neuropathy. *J Neuroophthalmol*. 2007;27:164-8.
  40. Jonas JB, Spandau UH, Harder B, et al. Intravitreal triamcinolone acetate for treatment of acute nonarteritic anterior ischemic optic neuropathy. *Graefes Arch Clin Exp Ophthalmol*. 2007;245:749-50.
  41. Radoi C, Garcia T, Brugniart C, et al. Intravitreal triamcinolone injections in non-arteritic anterior ischemic optic neuropathy. *Graefes Arch Clin Exp Ophthalmol*. 2014;252:339-45.
  42. Alten F, Clemens CR, Heiduschka P, et al. Intravitreal dexamethasone implant [Ozurdex] for the treatment of nonarteritic anterior ischaemic optic neuropathy. *Doc Ophthalmol*. 2014;129:203-7.
  43. Rootman DB, Gill HS, Margolin EA. Intravitreal bevacizumab for the treatment of nonarteritic anterior ischemic optic neuropathy: a prospective trial. *Eye*. 2013;27:538-44.
  44. Prescott CR, Sklar CA, Lesser RL, et al. Is intravitreal bevacizumab an effective treatment option for nonarteritic anterior ischemic optic neuropathy? *J Neuroophthalmol*. 2012;32:51-3.
  45. Pece A, Querques G, Quinto A, et al. Intravitreal ranibizumab injection for nonarteritic ischemic optic neuropathy. *J Ocul Pharmacol Ther*. 2010;26:523-7.
  46. Bajin MS, Selver OB, Taskin O, et al. Single intravitreal ranibizumab injection in eyes with acute non-arteritic anterior ischaemic optic neuropathy. *Clin Exp Optom*. 2011;94:367-70.
  47. Saatci AO, Taskin O, Selver OB, et al. Efficacy of intravitreal ranibizumab injection in acute nonarteritic ischemic optic neuropathy: a long-term follow up. *Open Ophthalmol J*. 2013;30;7:58-62.
  48. Ayhan Z, Kocaoğlu G, Yaman A, et al. Single intravitreal aflibercept injection for unilateral acute nonarteritic ischemic optic neuropathy. *Case Rep Ophthalmol Med*. 2015;78:32-41.
  49. Donmez O, Kocaoğlu G, Yaman A, et al. Unilateral akut non-arteritik iskemik optik nöropatide intravitreal aflibercept tedavisi intravitreal aflibercept treatment in acute unilateral non-arteritic optic neuropathy. *Ret-Vitr*. 2014;22:221-5.
  50. Wilhelm B, Lüdtke H, Wilhelm H; BRAION Study Group. Efficacy and tolerability of 0.2% brimonidine tartrate for the treatment of acute non-arteritic anterior ischemic optic neuropathy (NAION): a 3-month, double-masked, randomised, placebo-controlled trial. *Graefes Arch Clin Exp Ophthalmol*. 2006;244:551-8.
  51. Danylkova NO, Alcalá SR, Pomeranz HD, et al. Neuroprotective effects of brimonidine treatment in a rodent model of ischemic optic neuropathy. *Exp Eye Res*. 2007;84:293-301.
  52. Johnson LN, Gould TJ, Krohel GB. Effect of levodopa and carbidopa on recovery of visual function in patients with nonarteritic anterior ischemic optic neuropathy of longer than six months' duration. *Am J Ophthalmol*. 1996;121:77-83.
  53. Simsek T, Eryilmaz T, Acaroglu G. Efficacy of levodopa and carbidopa on visual function in patients with non-arteritic anterior ischaemic optic neuropathy. *Int J Clin Pract*. 2005;59:287-90.

54. Kumral, A., Genc, S., Ozer, E., Yilmaz, O., Gokmen, N., Koroglu, T. F., ... & Ozkan, H. Erythropoietin downregulates bax and DP5 proapoptotic gene expression in neonatal hypoxic-ischemic brain injury. *Neonatology*. 2006;89(3):205-210.
55. Gökçe S. Deneysel iskemik optik nöropatide vazopresin v1 reseptör antagonistinin optik sinir kan akımı otoregülasyonuna etkisi. *Tıpta Uzmanlık Tezi*. Adana 2006.
56. Wen R, Tao W, Li Y, et al. CNTF and retina. *Prog Retin Eye Res*. 2012;31:136-51.
57. Mathews MK, Guo Y, Langenberg P et al. Ciliary neurotrophic factor (CNTF) mediated ganglion cell survival in a rodent model of non-arteritic anterior ischaemic optic neuropathy (NAION). *Br J Ophthalmol*. 2015;99:133-7.
58. Arnold AC, Hepler RS, Lieber M, et al. Hyperbaric oxygen therapy for nonarteritic anterior ischemic optic neuropathy. *Am J Ophthalmol*. 1996;122:535-41.
59. Bojić L, Ivanisević M, Gosović G. Hyperbaric oxygen therapy in two patients with non-arteritic anterior optic neuropathy who did not respond to prednisone. *Undersea Hyperb Med*. 2002;29:86-92.
60. Hansen LL, Wiek J, Danisevskis M, et al. Isovolemic hemodilution on non-arteritic anterior optic neuropathy. Initial results of a randomized study. *Fortschr Ophthalmol*. 1991;88:487-9.
61. Wolf S, Schulte-Strake U, Bertram B, et al. Hemodilution therapy in patients with acute anterior ischemic optic neuropathy. *Ophthalmologe*. 1993;90:21-6.
62. Haas A, Uyguner I, Sochor GE, et al. Non-arteritic anterior ischemic optic neuropathy: long-term results after hemodilution therapy. *Klin Monbl Augenheilkd*. 1994;205:143-6.
63. Zhu XQ, Tian B, Yang WL, et al. The effect of retrobulbar injection with anisodamine on ocular blood velocity in anterior ischemic optic neuropathy. *Zhonghua Yan Ke Za Zhi* 2006;42:606-10
64. Zou AP, Parekh N, Steinhausen M. Dopaminergic effect of anisodamine on the microcirculation of the hydronephrotic kidney of rats. *J Tongji Med Univ*. 1991;11:65-72.
65. Schönfeld CL, Fischer M, Distelmaier P, et al. Recovery of visual function after administration of dabigatran etexilate. *Case Rep Ophthalmol* 2014;14:5:262-6.
66. Kajiwara K, Tsubota K, Hara Y. High dose urokinase thrombolysis and stellate ganglion block
67. Arnold A.C: Ischemic Optic Neuropathy, Diabetic Papillopathy and Papillophlebitis. In:Sadun A.A., Rubin R.M., Yanof M., Duker J.S., eds. *Ophthalmology*. Barcelona: Mosby; 1999; 11-7: 1-6.
68. Kanski J.J.: (1999). *Neuro-ophthalmology*. In: Kanski J.J., eds. *Clinical Ophthalmology*. (s:585-645) Glaskow, Butterworth-Heinemann.
69. Mustafa, Sharik, and Lekha Pandit. "Approach to diagnosis and management of optic neuropathy." *Neurology India*. 2014; 62.6:599.
70. DeVita EG, Miao M, et al. Optic neuropathy in ethambutol-treated renal tuberculosis. *J Clin Neuroophthalmol*. 1987; 7:77-86.
71. Purvin V, Kawasaki A, et al. Optic neuropathy in patients using amiodarone. *Arch Ophthalmol*. 2006;124:696-701.
72. Atilla, H. Travmatik ve toksik optik nöropati. *Turkish Journal of Ophthalmology/Turk Oftalmoloji Dergisi*. 2013; 43(2).
73. Leo-Kottler B, Wissinger B. Leber's hereditary optic neuropathy *Ophthalmologe*. 2011 ;108:1179-92.
74. Biousse V, Newman NJ. Neuro-ophthalmology of mitochondrial diseases. *Curr Opin Neurol*. 2003;16:35-43.
75. Newman NJ. Hereditary optic neuropathies: from the mitochondria to the optic nerve. *Am J Ophthalmol*. 2005;140:517-23.
76. Harding A, Sweeney M. Pedigree analysis in Leber hereditary optic neuropathy families with a pathogenic mtDNA mutation. *Am J Hum Genet*. 1995;57:77-86
77. Riordan-Eva P, Harding A, Da Costa J, Sanders M, Govan G, Sweeney M. The clinical features of Leber's hereditary optic neuropathy defined by the presence of a pathogenic mitochondrial DNA mutation. *Brain*. 1995;118(Pt 2):319-337.
78. Barboni P, Savini G, Valentino ML, et al. Leber's hereditary optic neuropathy with childhood onset. *Invest Ophthalmol Vis Sci*. 2006;47:5303-5309

79. Johns DR, Heher KL, Miller NR, Smith KH. Leber's hereditary optic neuropathy: clinical manifestations of the 14484 mutation. *Arch Ophthalmol.* 1993;111:495-498.
80. Ramos Cdo V, Bellusci C, Savini G, et al. Association of optic disc size with development and prognosis of Leber's hereditary optic neuropathy. *Invest Ophthalmol Vis Sci.* 2009;50:1666-1674.
81. Brown GC, & Shields JA. Tumors of the optic nerve head. *Survey of ophthalmology.* 1985;29(4), 239-264.
82. Sibony PA., Krauss HR, Kennerdell JS et al. Optic Nerves Sheath Meningiomas: Clinical Manifestations. *Ophthalmology.*1984;91(11):1313-1326.
83. Kim JL, Mendoza PR, Rashid A, Hayek B, Grossniklaus HE. Optic nerve lymphoma: 151 report of two cases and review of the literature. *Surv Ophthalmol.* 2015;60(2):153-65.
84. Öner H, Kaynak S, Koçak N, Kaynak N, Çıngıl G. Retina ve koroid neovaskularizasyonu ile seyreden radyasyon retinopatisi. *Retina-Vitreus.* 2002; 10: 283-287.
85. Wang BH, Robertson BC, Girotto JA et al. Traumatic optic neuropathy: A review of 61 patients. *Plastic and Reconstructive Surgery.* 2001;107:1655-64.
86. Spoor TC, Lensink, DB, Wilkinson MJ.,& Hartel WC. Treatment of traumatic optic neuropathy with corticosteroids. *American journal of ophthalmology.*1990; 110(6), 665-669.
87. Levin LA, Beck RW, Joseph MP, Seiff S, Kraker R, The International Opticnerve Trauma Study Group. The treatment of traumatic optic neuropathy. *TheInternational Optic Nerve Trauma Study.* *Ophthalmology.* 1999;106:1268-77.
88. Fujitani T, Inoue K, Takahashi T et al. Indirect traumatic optic neuropathy:visual outcome of operative and nonoperative cases. *Jpn J Ophthalmol.*1986;30:125-34.
89. Katz B, Weinreb Rn Wheeler DT. Anterior ischemic optic neuropathy and intraocular pressure. *Br J Ophthalmol.* 1990;74: 99-102.